US Patent 7767642 Therapeutic peptides for the treatment of metastatic cancer
All edits
Edits on 31 Oct, 2023
Golden AI
Edits made to:
Article (+353 characters)
Article
Patent abstract
Interaction between MUC1 and β-catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUC1. Interruption provides the beneficial effect of inhibiting, reducing, and/or retarding invasiveness and metastasis. Fusion polypeptides and antibodies are provided to achieve a therapeutic effect.
Edits on 26 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07767642 Therapeutic peptides for the treatment of metastatic cancer US Patent 7767642 Therapeutic peptides for the treatment of metastatic cancer
Infobox
Patent Number
0776764200
Patent Number
776764200
Edits on 22 Mar, 2023
Golden AI
Infobox
Is a
Patent Jurisdiction
Patent Number
077676420
Date of Patent
August 3, 2010
0Patent Application Number
114049590
Date Filed
April 17, 2006
0Official Website
Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Patent Jurisdiction
Patent Number
077676420
Date of Patent
August 3, 2010
0Patent Application Number
114049590
Date Filed
April 17, 2006
0Official Website
Patent Primary Examiner
Edits on 3 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 5 Dec, 2021
Golden AI
Edits made to:
Infobox (+7 properties)
US Patent 07767642 Therapeutic peptides for the treatment of metastatic cancer
Infobox
Is a
Patent jurisdiction
Patent number
07767642
Date of patent
August 3, 2010
Patent application number
11404959
Date Filed
April 17, 2006
Patent primary examiner
Find more entities like US Patent 7767642 Therapeutic peptides for the treatment of metastatic cancer
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
